Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Europe approves GSK and Sanofi’s next-gen COVID-19 booster vaccine VidPrevtyn Beta

By Brian Buntz | November 10, 2022

Sanofi-GSKThe European Commission has approved the VidPrevtyn Beta COVID-19 vaccine as a booster for individuals who are at least 18.

The vaccine is the first next-gen protein-based adjuvanted COVID-19 booster to win European approval.

Sanofi (Nasdaq:SNY) developed the vaccine based on the beta variant using GSK’s (NYSE:GSK) pandemic adjuvant.

After announcing the news, Sanofi shares were up 1.45% to $43.97 in early afternoon trading. GSK shares were up 2.42% to $33.21.

VidPrevtyn Beta is a monovalent, recombinant-protein vaccine developed by Sanofi, modeled on the Beta variant and including GSK’s pandemic adjuvant. The vaccine uses recombinant-protein technology found in Sanofi’s seasonal flu vaccines.

In July, GSK and Sanofi announced that their adjuvanted bivalent version of its vaccine was 72% efficacious against omicron in adults in a Phase 3 study.

GSK and Sanofi noted that the vaccine performed well in registrational trials when the omicron variant was predominant, including a Phase 3 primary efficacy study and two separate immunogenicity trials.

Sanofi tested VidPrevtyn Beta in two immunobridging trials to measure the immune response from the new vaccine relative to a previously approved vaccine.

In the COVIBOOST VAT013 study, the vaccine was administered to participants who had received two prior doses of Pfizer-BioNTech’s Comirnaty vaccine (BNT162b2).

In that study, VidPrevtyn Beta was also pitted against BNT162b2 as a booster. VidPrevtyn Beta offered a superior performance against the omicron BA.1 variant one month after administration. VidPrevtyn Beta led to approximately 2.5 times more neutralizing antibodies against the BA.1 variant and in an exploratory analysis involving the BA.4/BA.5 sublineages of omicron.

VidPrevtyn Beta offers protection against multiple strains of COVID-19, according to Thomas Triomphe, executive vice president of Sanofi Vaccines.

“The approval from the European Commission is an important step in providing further vaccine solutions to Europe for the coming autumn and winter,” said Phil Dormitzer, global head of vaccines R&D, GSK, in a news release.

The U.S. government contributed to the development of the vaccine through federal funds from Biomedical Advanced Research and Development Authority (BARDA).

In 2021, Sanofi announced that it halted the development of an mRNA-based COVID-19 vaccine.


Filed Under: clinical trials, Infectious Disease
Tagged With: GSK, Sanofi, VidPrevtyn Beta
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE